The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Pembrolizumab (Keytruda) for Metastatic Urothelial Cancer
(Pending Submission as of June 23, 2017)
Obinutuzumab (Gazyva) for Follicular Lymphoma
(Notification to Implement Issued as of June 19, 2017)
Fulvestrant (Falsodex) for Locally Advanced or Metastatic Breast Cancer
(Pending Submission as of June 14, 2017)
Midostaurin (Rydapt) for Acute Myeloid Leukemia
(Open for Input on Submission until June 26, 2017)
Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
(Pending Submission as of June 7, 2017)
Pembrolizumab (Keytruda) for classical Hodgkin Lymphoma
(Pending Submission as of May 30, 2017)